Article in The American journal of drug and alcohol abuse, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Andy C DeanDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Daicia AllenDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Megan McClintickDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Jean-Baptiste PochonDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Dara GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Mark A MandelkernNuclear Medicine, Veterans Administration of Greater Los Angeles System, Los Angeles, CA, USA.
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Funding
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural FunctionR01DA045162 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK, MOONEY, LARISSA JEANETTE · 2018 to 2022
$3.3M
Neurobehavioral Predictors of Cognitive Decline in Methamphetamine DependenceK23DA027734 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEAN, ANDREW CLARK · 2010 to 2014
$842k
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine UsersR21DA042347 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2017 to 2018
$528k
CYP2D6, brain structure, and cognitive function in methamphetamine dependenceR21DA034928 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEAN, ANDREW CLARK · 2013 to 2014
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dopamine D2/D3 receptor availability and working memory in stimulant use disorder. · full record | OpenQuestion